Ascentage Pharma Group International ((HK:6855)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: Ascentage Pharma Group Inc. is conducting a Phase 1 clinical study titled A Phase 1 Study to Evaluate Safety and Tolerability, Pharmacokinetics and Preliminary of APG-5918 in Healthy Subjects or Anemic Patients. The study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-5918, a potential treatment for anemia, highlighting its significance in addressing this common condition.
Intervention/Treatment: The study tests APG-5918, an experimental drug administered as oral tablets in doses of 10mg, 50mg, and 200mg. The purpose is to evaluate its effects on healthy individuals and anemic patients, with a placebo used for comparison in healthy subjects.
Study Design: This interventional study uses a randomized, parallel assignment model with double masking for participants and investigators. The primary purpose is treatment-focused, ensuring unbiased results in assessing APG-5918’s impact.
Study Timeline: The study began on February 22, 2023, with a primary completion date yet to be announced. The latest update was submitted on August 28, 2025, indicating ongoing recruitment and progress in the study.
Market Implications: The progress of this study could influence Ascentage Pharma’s stock performance, as positive results may boost investor confidence and market position. Competitors in the anemia treatment space will be closely monitoring these developments, given the potential impact on industry dynamics.
The study is currently recruiting, with further details available on the ClinicalTrials portal.